DexCom (DXCM +3.4%) gets a boost after Wunderlich initiates coverage with a Buy, saying that...

|By:, SA News Editor

DexCom (DXCM +3.4%) gets a boost after Wunderlich initiates coverage with a Buy, saying that growing visibility on the company's Gen4 approval process should push the stock near, or possibly through its $12 price target over the next 12 months.